AIP
AIMT

Ameritas Investment Partners’s Aimmune Therapeutics AIMT Stock Holding History

Ameritas Investment Partners’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,876
Closed -$134K – 3137
2020
Q3 		$134K Hold
3,876
– – 0.01% 1259
2020
Q2 		$65K Hold
3,876
– – ﹤0.01% 1682
2020
Q1 		$56K Hold
3,876
– – ﹤0.01% 1593
2019
Q4 		$130K Buy
3,876
+267
+7% +$7.46K 0.01% 1355
2019
Q3 		$76K Hold
3,609
– – ﹤0.01% 1641
2019
Q2 		$75K Hold
3,609
– – ﹤0.01% 1683
2019
Q1 		$81K Hold
3,609
– – ﹤0.01% 1606
2018
Q4 		$86K Hold
3,609
– – ﹤0.01% 1489
2018
Q3 		$98K Hold
3,609
– – ﹤0.01% 1591
2018
Q2 		$97K Buy
3,609
+520
+17% +$15.9K ﹤0.01% 1574
2018
Q1 		$98K Hold
3,089
– – ﹤0.01% 1508
2017
Q4 		$117K Hold
3,089
– – 0.01% 1415
2017
Q3 		$66K Hold
3,089
– – ﹤0.01% 1709
2017
Q2 		$64K Buy
3,089
+1,041
+51% +$19.9K ﹤0.01% 1747
2017
Q1 		$45K Buy
+2,048
New +$42K ﹤0.01% 1930

Ameritas Investment Partners's AIMT Position: Q4 2020 in Review

Ameritas Investment Partners sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 3,876 shares — an estimated $134K sold.

Ameritas Investment Partners first reported a position in AIMT in Q1 2017 and held it in 15 quarters. The position peaked at $134K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Ameritas Investment Partners reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Ameritas Investment Partners sold 3,876 Aimmune Therapeutics shares in Q4 2020, an estimated $134K.
  • Ameritas Investment Partners first reported a position in Aimmune Therapeutics in Q1 2017 and held it in 15 quarters.
  • Ameritas Investment Partners's Aimmune Therapeutics position peaked at $134K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Ameritas Investment Partners's 13F filing for Q4 2020, filed 12 Feb 2021.